Combination Therapy May Provide New Treatment Option for Patients with Lymphoma

The combination of Monjuvi (tafasitamab), an anti-CD19 antibody, and Revlimid (lenalidomide) achieved prolonged remission and survival benefit in patients with relapsed or refractory diffuse large B-cell lymphoma.

Researchers presented this long-term data from the phase 2 L-MIND study at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

“There was really an interest in developing new treatment options for these patients,” said Dr. Gilles Salles, chief of the lymphoma service at Memorial Sloan Kettering Cancer Center and one of the study authors, in an interview with CURE®. “And the strategy that was used in the L-MIND study is a strategy which is a combination of a monoclonal antibody directed against CD19, called tafasitamab (Monjuvi), which has been engineered in order to promote the tumor cell killed by the immune system.”

Salles added that this treatment approach may provide an option for patients in the second- or third-line of therapy who aren’t eligible for transplant.

Transcription:

There was really an interest in developing new treatment options for these patients. And the strategy that was used in the L-MIND study is a strategy which is a combination of a monoclonal antibody directed against CD19, called tafasitamab (Monjuvi), which has been engineered in order to promote the tumor cell killed by the immune system. And to reinforce the activity of these antibodies that have been evaluated initially as a single agent, this was combined with an agent that we know for many years, which is lenalidomide (Revlimid), which increased the cytotoxic activity of our immune cell. So that was the intent of the study, to try to deliver to patients in second or third line of therapy who were not transplant-eligible, another treatment approach that may provide them substantial benefits.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.